Cost Minimization Analysis (CMA) of XELOX versus MFOLFOX6 in the treatment of colorectal cancer in a public hospital in Brazil

Introduction: Cancer worldwide is a public health problem with perspective of 20 million new cases by 2025. Colorectal cancer (CRC) ranked the third most incident tumor in world and fourth Brazil. Hence economic impact care for these patients significant. Objectives: The purpose this paper was to evaluate effectiveness conduct assessment XELOX mFOLFOX6, two chemeoterapic protocols used adjuvant metastatic treatment colorectal cancer, university hospital located at Rio Grande do Sul. Methodology: We conducted systematic reviews using Pubmed, Science Direct Google Scholar databases analysis randomized clinical trials (RCT), or meta-analyses, comparing FOLFOX and/or palliative setting CRC, among January 1st, 1995 December 31, 2015. also analyzed quality studies GRADE checklist. In cost analysis, we time-driven activity-based costing (TDABC) microcosting method identify expenses medicines, materials, laboratory imaging exams, outpatient inpatient visits, human administrative resources determine individual per patient. study, analysed medical records all (N:36) who began palliate CRC one years 2013 2014 our hospital. information about direct costs were collected electronic record system. For non-medical financial reports. Results: identified five studies: RCT four including three treatments. These showed therapeutic equivalence between FOLFOX. minimization revealed an average R$ 8,407.13 6,946.47 treatment, mFOLFOX6 9,925.98 8,036.95, respectively. Sensitivity maintained dominance XELOX. Conclusion: From perspective, least costly alternative however, further analyses higher number inclusion other components are necessary order confirm this.